Research Progress on Shengxian Decoction in the Treatment of Non-Small Cell Lung Cancer
DOI:
https://doi.org/10.53469/jcmp.2024.06(12).18Keywords:
Non-small cell lung cancer, Shengxian decoction, Research progressAbstract
Lung cancer has the highest incidence and mortality rates among malignant tumors in China, with non-small cell lung cancer (NSCLC) accounting for 80%-85% of lung cancer cases. In recent years, treatment methods such as surgery, radiotherapy, and chemotherapy have advanced significantly; however, issues such as numerous complications, severe side effects, and increased drug resistance remain. Traditional Chinese Medicine (TCM) offers a multi-component, multi-target, and multi-pathway approach for treating NSCLC without these drawbacks, which has attracted considerable attention. The fundamental pathogenesis of NSCLC in TCM is characterized by Qi deficiency and Qi sinking, encapsulated in the saying, "When the righteous Qi is present, evil cannot invade." The great Qi resides in the chest, and its sinking makes one susceptible to cancer toxins. Shengxian Decoction is a representative formula for treating Qi sinking syndrome. Clinical and experimental studies have confirmed that Shengxian Decoction is effective against NSCLC, demonstrating good results in inhibiting tumor proliferation, promoting tumor cell apoptosis, blocking tumor cell invasion and metastasis, reducing inflammation, and preventing tumor cell immune evasion. Research at the levels of network pharmacology and molecular biology has also identified several active components in Shengxian Decoction with anti-lung cancer properties, which exert their effects through multiple targets. Currently, there is a lack of comprehensive literature on the use of Shengxian Decoction for treating NSCLC. This paper reviews the effects of Shengxian Decoction on NSCLC from the perspectives of theoretical origins, material basis, network pharmacology, and experimental and clinical studies, aiming to provide a reference for further research on the pharmacological effects and clinical applications of Shengxian Decoction.
References
Liu Zongchao; Li Zhexuan; Zhang Yang, et al. Interpretation on the report of Global Cancer Statistics 2020 [J]. Journal of Multidisciplinary Cancer Management (Electronic Version), 2021,7(02):1-14.
General Office of National Health Commission of the People's Republic of China. Clinical Practice Guideline for Primary Lung Cancer (2022 Version) [J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 549-570.
Wang Wenjie, Xu Chen zhen, Gao Minglang, et al. Interpretation of the NCCN clinical practice guidelines in oncology for non-small cell lung cancer (version 2.2023) [J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023,30(05):660-664.
Chen Jian, Meng Jingjing, Zhao Yongsheng, et al. Influencing factors of postoperative recurrence and metastasis in patients with non-small cell lung cancer undergoing minimally invasive thoracoscopic resection [J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine, 2023,29(03):343-347.
Zhai Zonggang, Chen Fei, Qiao Hua. Comparative Analysis of Curative Effect of Different Surgical Methods in Patients with Non-small Cell Lung Cancer [J]. The Practical Journal of Cancer, 2023, 38(05): 855-858.
Yuan Meng, Han Zhengbo, Ma Jietao, et al. Safety and Efficacy of Chemotherapy and Radiotherapy for the Treatment of Unresectable Locally Advanced Non-small Cell Lung Cancer [J]. Journal of China Medical University, 2017,46(12):1124-1128.
Wu Guanjin, Liu Yi, Jiao Lijing, et al. Status in the clinical application of epidermal growth factor receptor-tyrosinase kinase inhibitor resistance pathway inhibitors in non-small cell lung cancer [J]. The Chinese Journal of Clinical Pharmacology, 2023, 39(06): 893-897.
Zhang Shina, Zheng Aihua, Liu Hongmei. Clinical Observation on the Treatment of Acute Respiratory Distress Syndrome with Shengxian Decoction [J]. Asia-Pacific Traditional Medicine, 2020, 16(06): 146-149.
Su Jun, Li Lei, Zhong Liping, et al. A Clinic Observation on 38 Patients with Obstructive Sleep Apnea Hypopnea Syndrome Treated by Shengxian Decoction in Combination with Duxil [J]. Journal of Traditional Chinese Medicine, 2010,51(07):600-602.
Yang Shengli, Hu Hanfei. Effect of Treatment With Shengxian Decoction in Acute Exacerbation of Chronic Obstructive Pulmonary Disease [J]. China Continuing Medical Education, 2019,11(16):139-141.
Qiu Yuan, Gao Jihui. Clinical Effect Analysis of Shengteng Decoction Combined with Traditional Chinese Medicine Cardiac Rehabilitation Exercise for Unstable Angina Pectoris [J]. World Journal of Complex Medicine, 2019,5(11):23-25.
Liu Sixin, Yu Shenglan. Clinical Study of Shengxian Decoction Combined with Modified Xiaoxianxiong Decoction in the Treatment of 33 Cases of Acute Coronary Syndrome with Conventional Western Medicine [J]. Traditional Chinese Medicinal Research, 2012,25(01):20-22.
Li Jie, Hua Baojin, Lin Hongsheng. Analysis on Syndrome Differentiation in Treating Postoperative Symptoms of Malignant Chest Tumor Based on Qi Collapse Theory [J]. Journal of Traditional Chinese Medicine, 2014,55(21):1822-1825.
Yao Lifang. Clinical Efficacy of Modified Shengxian Decoction in Treating Fatigue Related to Non-Small Cell Lung Cancer with Lung-Spleen Qi Deficiency [J]. Chinese Journal of Cancer Prevention and Treatment, 2019,26(S1):60-61.
Wu Qiansheng, Li Mengli, Xia Mengjiao, et al. Treatment of Lung Cancer after Chemotherapy Based on Grand Qi Sinking [J]. Shandong Journal of Traditional Chinese Medicine, 2019,38(03):221-224.
Chen Jiahao, Lin Yang, Wang Dongxue, et al. Research Progress in Chemical Constituents and Pharmacological Action of Shengxian Decoction [J]. Chemistry & Bioengineering, 2021,38(04):10-18.
Wang M, Li H, Gao Y, et al. A multidimensional strategy to rapidly identify the chemical constituents in Shengxian Decoction by using ultra-performance liquid chromatography coupled with ion mobility spectrometry quadrupole time-of-flight mass spectrometry[J]. J Sep Sci, 2022,45(16):3115-3127.
Zhou Lixia, Guan Hongquan, Ma Xiande, et al. Effect of calycosin on proliferation and apoptosis of lungadenocarcinoma cell line SPC-A1 [J]. China Journal of Modern Medicine, 2020,30(11):1-6.
Cheng X D, Gu J F, Yuan J R, et al. Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC-alpha/ERK1/2 pathway: An in vitro investigation[J]. Mol Med Rep, 2016, 13(4): 3709-3710.
Li Ziquan, Meng Xiangjiao. Effect of Formononetin on Proliferation and Apoptosis of Human Non-Small Cell Lung Cancer Cell and Its Relevant Mechanism [J]. Chinese Journal of Experimental Traditional Medical Formulae, 2016,22(20):138-142.
Yang Y, Zhao Y, Ai X, et al. Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis[J]. Int J Clin Exp Pathol, 2014,7(12):8453-8461.
Xu F, Cui W Q, Wei Y, et al. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling[J]. J Exp Clin Cancer Res, 2018,37(1):207.
Luo Ting, Wang Xiaobo, Yu Shiqun, et al. Daidzein affects proliferation and apoptosis in non-small cell lung cancer cells: role of p53 signaling pathway [J]. Chinese Pharmacological Bulletin, 2023,39(03):431-438.
Cheng Qiong, Li Zhen, Chen Jinhui, et al. Effect of daidzein on proliferation and migration of lung cancer cells and its related mechanism [J]. Chinese Pharmacological Bulletin, 2020,36(02):245-249.
Lu Wenquan, Qiu Yan, Pang Tao, et al. Study on Inhibitory Mechanism of Timosaponin B-Ⅱ on the Proliferation and Migration of Human Lung Cancer A549 Cells [J]. China Pharmacy, 2016, 27(10): 1346-1349.
Yuan Zhiren, Yin Nanchang. Study on the Molecular Mechanism of Mangiferin in the Treatment of Non-small Cell Lung Cancer [J]. Acta Scientiarum Naturalium Universitatis Nankaiensis, 2023, 56(02): 45-52.
Phan T, Shahbazzadeh F, Pham T, et al. Alpha-mangostin inhibits the migration and invasion of A549 lung cancer cells[J]. PeerJ, 2018,6:e5027.
Wu Jing, Wang Tingxiang, Wei Nan, et al. Ferulic acid inhibits lung cancer growth and its mechanism [J]. Zhejiang Medical Journal, 2018,40(12):1303-1306.
Guo Feng, Zhao Ruimin, Li Jingliang, et al. Ferulic acid inhibits lung cancer cell proliferation and metastasis by regulating JAK2/STAT6 immune signaling pathway [J]. Chinese Journal of Immunology, 2021,37(04):459-462.
Shen Bo, Zhang Hao, Mao Shuang, et al. Saikasaponin D Regulates VEGF/VEGFR2 Signaling Pathway to Inhibit Non-small Cell Lung Cancer Cell Proliferation, Migration and Invasion [J]. Medical Innovation of China, 2021,18(08):22-27.
Zu Feicui, Wei Haixia, Han Chunlan, et al. Effect of JAK2/STAT3 signaling pathway on the proliferation and apoptosis of non-small cell lung cancer H460 cells regulating by saikosaponin D [J]. Journal of Clinical Pulmonary Medicine, 2023,28(05):718-724.
Luo W, Liu Q, Jiang N, et al. Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells[J]. Biosci Rep, 2019,39(9).
Du Y, Jia C, Liu Y, et al. Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-kappaB Signaling Pathway[J]. Front Pharmacol, 2020,11:610772.
Chai R, Xu C, Lu L, et al. Quercetin inhibits proliferation of and induces apoptosis in non-small-cell lung carcinoma via the lncRNA SNHG7/miR-34a-5p pathway[J]. Immunopharmacol Immunotoxicol, 2021, 43(6):693-703.
Xingyu Z, Peijie M, Dan P, et al. Quercetin suppresses lung cancer growth by targeting Aurora B kinase[J]. Cancer Med, 2016,5(11):3156-3165.
Li Tao, Gong Changzhi, Zhu Jiabin, et al. Study on the mechanism of puerarin in inhibiting the proliferation, invasion and migration of non-small cell lung cancer A549 cells [J]. Journal of Modern Oncology, 2022,30(01):16-21.
Zhang Yuxin, Zhang Zhenzhen, Zhao Ligang, et al. Puerarin Inhibits the Proliferation, Invasion, and Migration of Non-small Cell Lung Cancer Cells through Regulating miR-490/Denticleless E3 Ubiquitin Protein Ligase [J]. Acta Academiae Medicinae Sinicae, 2022, 44(01): 91-101.
Yang Shenghui, Huang Yanjing, Mo Anwei, et al. Effect of Kaempferol on the Proliferation of Non-small Cell Lung Cancer A549 Cells by Regulating miR21 [J]. Chinese Journal of Modern Applied Pharmacy, 2020,37(13):1557-1562.
Zhang Jing, Shi Xiaoyu, Meng Wei, et al. Kaempferol inhibits invasion and migration of non-small cell lung cancer A549 cells by down-regulating ERRα expression [J]. Chinese Journal of Cancer Biotherapy, 2018,25(12):1230-1236.
Park J C, Lee Y J, Choi H Y, et al. In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell[J]. Evid Based Complement Alternat Med, 2014, 2014: 478653.
Dai Qun, Chen Zhe, Ge Yuqing, et al. Mechanism of platycodin D-induced humane long cancer cells A549 apoptosis [J]. China Journal of Chinese Materia Medica, 2012,37(17):2626-2629.
Wu Jingyuan, Xu Bowen, Li Jie, et al. Exploring the Molecular Biological Mechanism of Shengxian Decoction in the Treatment of Non-small Cell Lung Cancer Based on Network Pharmacology[J]. World Journal of Integrated Traditional and Western Medicine, 2021,16(03):490-499.
Ni J, Wang X, Stojanovic A, et al. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1alpha Unleashes NK Cell Activity[J]. Immunity, 2020,52(6):1075-1087.
Shurin M R, Umansky V. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy[J]. J Clin Invest, 2022,132(9).
Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021,6(1):263.
Wu Borong, Jin Meng, Wang Weizhen, et al. Immune Function and Molecular Mechanism of the PI3K/AKT Signaling Pathway in Tumor Regulation [J]. Chinese Journal of Clinical Rational Drug Use, 2013,6(16):135-137.
Zhao Lianmei, Sun Jiawei, Yan Xi, et al. Study for effect of Shengxiantang on invasion and metastasis of lung cancer A549 cell in vitro [J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2011, 26(09): 2147-2150.
Liu Wei, Huang Wei, Li Ruiqin. Research Progress on the Related Mechanisms of the MAPK/ERK Signaling Pathway in Tumorigenesis [J]. Modern Medicine Journal of China, 2016,18(08):97-100.
Li Xiaohong. Study on the Effect of Shengxian Decoction on Proliferation of Human Lung Adenocarcinoma A549 Cells [D]. Chengdu University of Traditional Chinese Medicine, 2020.
Li K, You F, Zhang Q, et al. Chemical and Biological Evidence of the Efficacy of Shengxian Decoction for Treating Human Lung Adenocarcinoma [J]. Front Oncol, 2022,12:849579.
Chen Yujia. Retrospective Study on End-of-Life Treatment of 334 Lung Cancer Patients [D]. Beijing University of Chinese Medicine, 2015.
Chen Yujia, Xu Shu, Hu Kaiwen. Effects of Different Treatment Modes on Quality of Life of End-stage Lung Cancer Patients: A Retrospective Study [J]. Journal of Traditional Chinese Medicine, 2018,59(12):1039-1041.
Su Chunyu, Zhu Guanghui, Li Jie. Symptoms Distribution Rules of Postoperative Non-small Cell Lung Cancer Patients and Intervention Effect of Modified Shengxian Decoction [J]. Journal of Traditional Chinese Medicine, 2020,61(07):601-606.
Zhang Shiwen, Wang Xin, Huang Lin, et al. Efficacy of Modified Shengxian Decoction Combined with Siwu Decoction in Treating Fatigue in Lung Malignancies [J]. Chinese Journal of Gerontology, 2023,43(06):1308-1312.
Su Hang, Zhao Qiumei. Effects of Modified Shengxian Decoction on Tumor-Related Fatigue during Chemotherapy in Patients with Non-Small Cell Lung Cancer with Lung-Spleen Qi Deficiency [J]. Electronic Journal of Clinical Medicine Literature, 2019, 6(A0): 16-17.
Zhou Mei, Kou Yan, Wang Hongli. Effect of Modified Shengxian Decoction (升陷汤加减) Combined with TP Chemotherapy on Non-Small Cell Lung Cancer and Its Influence on Inflammatory Cytokines and Immune Function [J]. Liaoning Journal of Traditional Chinese Medicine, 2022,49(06):84-87.
Sun Gen. Clinical Study on the Treatment of Tumor-Related Fatigue in Patients with Non-Small Cell Lung Cancer with Lung-Spleen Qi Deficiency using Modified Shengxian Decoction [D]. Henan University of Traditional Chinese Medicine, 2018.
Dai Yujin. Advances of the occurrence mechanism on cancer [J]. Journal of Biology, 2004(06):4-7.
Yao Dan, Su Baoke, Wang Jingqi, et al. Study on the Correlation between Qi Deficiency Syndrome and Immune Function in Chronic Obstructive Pulmonary Disease [J]. Inner Mongolia Journal of Traditional Chinese Medicine, 2022,41(10):140-144.
Huang Wei, Qian Meng, Xie Ming. Clinical Study Progress in Tumor Radiotherapy Combined with Traditional Chinese Medicines with Synergistic and Attenuated Effects [J]. China Pharmacist, 2017, 20(08): 1374-1381.
Wang Xueyu, He Dan, Sun Jinfang. Research Progress on Traditional Chinese Medicine in the Treatment of Chemotherapy-related Nausea and Vomiting of Lung Cancer [J]. GUANGMING JOURNAL OF CHINESE MEDICINE, 2022, 37(08): 1503-1506.
Zhang Qianru. Study on the Efficacy of Shengxian Decoction in Treating Early Parkinson's Disease with Autonomic Dysfunction and Qi Deficiency [D]. Shanghai University of Traditional Chinese Medicine, 2019.
Banerjee P, Eckert A O, Schrey A K, et al. ProTox-II: a webserver for the prediction of toxicity of chemicals[J]. Nucleic Acids Res, 2018, 46(W1): W257-W263.
Wei Z, Gao Y, Meng F, et al. iDMer: an integrative and mechanism-driven response system for identifying compound interventions for sudden virus outbreak[J]. Brief Bioinform, 2021,22(2):976-987.
Zhou Zhi, Wu Zhiqiang, Wei Qizhi, et al. Effects of Mangiferin on the Nervous, Respiratory, and Cardiovascular Systems and Its Acute Toxicity Study [J]. Chinese Journal of Traditional Medical Science and Technology, 2011,18(04):328-329.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Huarui Liao, Jie Zhu
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
